FDAnews
www.fdanews.com/articles/145354-watson-confirms-favorable-district-court-ruling-in-generic-sanctura-xr-patent-suit

Watson Confirms Favorable District Court Ruling in Generic Sanctura XR Patent Suit

April 4, 2012
Watson Pharmaceuticals confirmed that the United States District Court for the District of Delaware has ruled that the asserted claims of patent nos. ‘978, ‘359, ‘448 Patent, ‘449 and ‘635 for Sanctura XR (trospium chloride extended-release capsules) are invalid.
MarketWatch